Ahmad Thaniyyah, Wang Jie, Velez Ana Karen, Suarez-Pierre Alejandro, Clement Kathleen C, Dong Jie, Sebestyen Krisztian, Canner Joseph K, Murphy Michael P, Lawton Jennifer S
Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University, Baltimore, Md.
Department of Surgery, University of Colorado School of Medicine, Aurora, Colo.
JTCVS Open. 2021 Aug 8;8:338-354. doi: 10.1016/j.xjon.2021.07.036. eCollection 2021 Dec.
Myocytes exposed to stress exhibit significant swelling and reduced contractility. These consequences are ameliorated by adenosine triphosphate-sensitive potassium (K) channel opener diazoxide (DZX) via an unknown mechanism. K channel openers also provide cardioprotection in multiple animal models. Nitric oxide donors are similarly cardioprotective, and their combination with K activation may provide synergistic benefit. We hypothesized that mitochondria-targeted S-nitrosating agent (MitoSNO) would provide synergistic cardioprotection with DZX.
Myocyte volume and contractility were compared following Tyrode's physiologic solution (20 minutes) and stress (hyperkalemic cardioplegia [CPG] ± DZX; n = 5-20 each; 20 minutes) with or without MitoSNO (n = 5-11 each) at the end of stress, followed by Tyrode's solution (20 minutes). Isolated mouse hearts received CPG ± DZX (n = 8-10 each) before global ischemia (90 minutes) with or without MitoSNO (n = 8 each) at the end of ischemia, followed by reperfusion (30 minutes). Left ventricular (LV) pressures were compared using a linear mixed model to assess the impact of treatment on the outcome, adjusting for baseline and balloon volume.
Stress (CPG) was associated with reduced myocyte contractility that was prevented by DZX and MitoSNO individually; however, their combination was associated with loss of cardioprotection. Similarly, DZX and MitoSNO improved LV function after prolonged ischemia compared with CPG alone, and cardioprotection was lost with their combination.
MitoSNO and DZX provide cardioprotection that is lost with their combination, suggesting mutually exclusive mechanisms of action. The lack of a synergistic beneficial effect informs the current knowledge of the cardioprotective mechanisms of DZX and will aid planning of future clinical trials.
暴露于应激状态下的心肌细胞会出现明显肿胀且收缩力降低。三磷酸腺苷敏感性钾(K)通道开放剂二氮嗪(DZX)可改善这些后果,但其作用机制尚不清楚。K通道开放剂在多种动物模型中也具有心脏保护作用。一氧化氮供体同样具有心脏保护作用,它们与K通道激活剂联合使用可能会产生协同效益。我们推测线粒体靶向亚硝基化剂(MitoSNO)与DZX联合使用可提供协同心脏保护作用。
在应激结束时,比较在有或没有MitoSNO(每组n = 5 - 11)的情况下,用台氏生理溶液处理20分钟以及应激(高钾停搏液[CPG]±DZX;每组n = 5 - 20;20分钟)后心肌细胞体积和收缩力,随后再用台氏溶液处理20分钟。分离的小鼠心脏在全心缺血90分钟前接受CPG±DZX(每组n = 8 - 10),在缺血结束时给予或不给予MitoSNO(每组n = 8),随后进行再灌注30分钟。使用线性混合模型比较左心室(LV)压力,以评估治疗对结果的影响,并对基线和球囊体积进行校正。
应激(CPG)导致心肌细胞收缩力降低,DZX和MitoSNO单独使用均可预防;然而,它们联合使用时心脏保护作用丧失。同样,与单独使用CPG相比,DZX和MitoSNO在长时间缺血后可改善左心室功能,但联合使用时心脏保护作用丧失。
MitoSNO和DZX均可提供心脏保护作用,但联合使用时这种作用丧失,提示它们的作用机制相互排斥。缺乏协同有益作用为目前对DZX心脏保护机制的认识提供了信息,并将有助于未来临床试验的规划。